BNP Paribas Financial Markets Has $991,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

BNP Paribas Financial Markets lessened its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 36.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 22,937 shares of the company's stock after selling 13,394 shares during the period. BNP Paribas Financial Markets' holdings in Scholar Rock were worth $991,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Ameriprise Financial Inc. boosted its holdings in Scholar Rock by 79.5% in the fourth quarter. Ameriprise Financial Inc. now owns 18,816 shares of the company's stock valued at $813,000 after acquiring an additional 8,331 shares during the last quarter. Boxer Capital Management LLC bought a new position in Scholar Rock in the fourth quarter valued at about $32,415,000. RA Capital Management L.P. bought a new position in Scholar Rock in the fourth quarter valued at about $761,000. Monashee Investment Management LLC bought a new position in Scholar Rock in the fourth quarter valued at about $1,945,000. Finally, Northern Trust Corp boosted its holdings in Scholar Rock by 20.3% in the fourth quarter. Northern Trust Corp now owns 746,527 shares of the company's stock valued at $32,265,000 after acquiring an additional 125,904 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reiterated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Trading Down 1.5%

NASDAQ:SRRK traded down $0.46 during mid-day trading on Friday, hitting $30.00. The company had a trading volume of 825,200 shares, compared to its average volume of 1,267,164. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The business's fifty day moving average is $30.85 and its two-hundred day moving average is $35.93. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The firm has a market cap of $2.85 billion, a P/E ratio of -12.77 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the previous year, the business earned ($0.59) earnings per share. As a group, research analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Scholar Rock

In other news, CFO Edward H. Myles sold 142,292 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at $3,966,108.90. This trade represents a 56.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Katie Peng sold 1,006 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now directly owns 30,319 shares in the company, valued at approximately $1,043,579.98. This represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 154,798 shares of company stock valued at $5,482,238. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.